Niagen Bioscience AI Stock Analysis
Niagen Bioscience (OCD1) AI Stock Analysis
Niagen Bioscience
(Frankfurt:OCD1)
No summary available
Niagen Bioscience (OCD1) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 163.54M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- 16.3
- Beta (1Y)
- 1.07
- Revenue Growth
- -6.71%
- EPS Growth
- -53.86%
- Country
- Germany
- Employees
- 117
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Biotechnology
Niagen Bioscience Business Overview & Revenue Model
Company Description
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that con...
Niagen Bioscience Earnings Call Summary
The call was broadly constructive, supported by positive operating cash flow, a debt-free balance sheet, resilient direct-to-consumer demand, expanded distribution, progress in skincare and Niagen Plus, and advancing pharmaceutical and scientific programs. These positives were tempered by a 10% year-over-year decline in Tru Niagen revenue, increased competition, a 160 basis point gross-margin decline, a quarterly net loss and higher expected spending.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Niagen Bioscience said each business is well positioned for significant growth in 2027, expects fourth quarter revenue to improve sequentially from the third quarter, expects to begin commercialization of a new NR salt form in early 2027, expects a topical product incorporating Niagen to reach the market in early 2027, plans to launch a new branded skin care product in the first half of 2027, and plans to begin first-in-human studies of NB4168 in 2027, subject to completion of the necessary development work and regulatory clearance; the company is presently thinking about 5,000 participants and a 3-year term for the Mass General Brigham prevention trial, expects China cross-border sales to be more than 2 to 3x compared to last year, expects malate to reduce cost of goods in some way in 2027 and in a significant way after that, and expects increased selling and marketing expenses, R&D investments and G&A spending.
Niagen Bioscience Risk Analysis
Niagen Bioscience disclosed 55 risk factors in its most recent earnings report. Niagen Bioscience reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskNiagen Bioscience Peers Comparison
Overall Rating
ALEC58Neutral
ACOG49Neutral
ACIU45Neutral
BIOA41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| 58Neutral | $378.15M | 7.26 | 112.21% | ― | 151.23% | ― | |
| 49Neutral | $182.94M | -6.10 | -53.52% | ― | 171.93% | 0.11% | |
| 45Neutral | $216.78M | -4.45 | -104.05% | ― | 384.77% | 38.30% | |
| 41Neutral | $255.07M | -2.18 | -31.42% | ― | 45.33% | -20.81% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:OCD1 | Niagen Bioscience, Inc. | 1.87 | -3.78 | -66.90% | |
| ACIU | AC Immune | 2.13 | -0.97 | -31.29% | |
| ALEC | Alector | 2.54 | 1.30 | 104.84% | |
| ACOG | Alpha Cognition Inc | 8.30 | 2.40 | 40.68% | |
| TELO | Telomir Pharmaceuticals, Inc. | 0.49 | -0.91 | -65.00% | |
| BIOA | BioAge Labs, Inc. | 5.55 | -2.76 | -33.21% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
